Introduction
Proof of effectiveness and outcome benefits is increasingly important for new medical technologies. Beside safety and efficacy required for regulatory approvals, medical users often request outcome studies before starting to use a new technology. These developments present new challenges for new medical technologies, especially for non-therapeutic technologies like patient monitoring.
Challenges from Outcome Studies
Monitoring technologies are typically extensively tested for precision, accuracy, sensitivity and specificity of their measurements or diagnostic output. But they only can have a direct positive impact on outcomes when they have fewer complications than a competing technology with the same monitoring functionality. For nontherapeutic technologies that have relevant side-effects their outcome benefits must outweigh their risks. Such benefits are related to therapeutic interventions that may be initiated or guided by monitoring results.
Outcome Studies with Monitoring Technologies
Outcome studies with patient monitoring require that the respective monitoring technology is embedded in a suitable therapeutic protocol which is explicit and implementable. Therapeutic interventions must have the potential to change outcome and timing of monitoring and intervention must be adequate. Moreover, it should be considered problematic to combine new monitoring technologies with new, not well established treatment modalities, as interferences may be unpredictable. A target variable with therapeutic relevance should be selected. This target variable should also be different from the investigated monitoring parameters. Finally, adequate therapeutic endpoints should be defined and investigated in adequate patient populations.
Conclusions
Outcome studies with patient monitoring technologies require careful design in the context of therapeutic protocols. While such studies are often not required for regulatory approval they are essential to determine the clinical utility and value of monitoring technologies.
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